Related Experiment Video

Updated: May 19, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

[Multi-state model in the evaluation of outcome on mild cognitive impairment to Alzheimer's disease]

Jian-wei Gao1, Shan-shan Yang, Li-ye Zhou

  • 1School of Public Health, Shanxi Medical University, Taiyuan 030001, China.

Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|August 14, 2012
PubMed
Abstract

Insights

This study introduces a multi-state Markov model to predict mild cognitive impairment (MCI) progression to Alzheimer's disease (AD). Key factors like gender, age, and hypertension influence disease transitions, informing targeted prevention strategies.

Area of Science:

  • Gerontology and Epidemiology
  • Biostatistics and Health Modeling

Background:

  • Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease (AD), necessitating early intervention strategies.
  • Understanding the dynamic progression of cognitive decline is crucial for developing effective preventative measures in the elderly population.

Purpose of the Study:

  • To introduce and apply a multi-state Markov model for predicting the progression from MCI to AD.
  • To identify significant risk factors associated with different stages of cognitive decline for targeted interventions.

Main Methods:

  • A three-state homogeneous Markov model was constructed using data from six follow-up visits.
  • States represented MCI (state 1), moderate to severe cognitive impairment (state 2), and AD (state 3).
  • Model fit was assessed, and transition probabilities and survival curves were generated.

Main Results:

  • Gender, age, and hypertension were significant predictors for progression from MCI to moderate/severe impairment (state 1 to 2).
  • Age, education level, and reading habits influenced the transition from moderate/severe impairment back to MCI (state 2 to 1).
  • Gender, age, hypertension, diabetes, and ApoE ε4 genotype were significant predictors for progression from moderate/severe impairment to AD (state 2 to 3).

Conclusions:

  • Phase-by-phase prevention strategies, tailored to the specific risk factors at each stage, can help delay cognitive decline.
  • The multi-state Markov model effectively simulates disease natural history and dynamically evaluates chronic disease progression with multiple factors.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...